“Strong financial performance combined with disciplined strategy enables healthcare leaders to deliver sustainable growth while consistently rewarding shareholders across global markets.”
PureHealth: Healthcare leader reinforces growth strategy and investor confidence with solid financial results and global expansion momentum
PureHealth has reinforced its position as a leading healthcare powerhouse in the region after shareholders approved a cash dividend of AED 600 million for the financial year ending 31 December 2025, reflecting strong financial performance and sustained growth momentum.
The approved dividend, representing approximately 30% of net profit, underscores the Group’s commitment to delivering consistent returns to shareholders while maintaining a disciplined approach to capital allocation.
The decision follows a year of impressive financial results, with the company reporting AED 2 billion in net profit, marking a 17.7% year-on-year increase, supported by strong operational performance across both its healthcare and insurance segments.
Revenue for the year reached AED 27.3 billion, up 5.7% compared to the previous year, while EBITDA rose by 16.1% to AED 4.8 billion, driven by efficiency gains and contributions from international acquisitions.
The dividend approval reflects the Group’s robust balance sheet, recurring earnings base, and strong cash flow generation, positioning it to reward investors while continuing to invest in long-term growth initiatives.
Chairman Kamal Al Maazmi highlighted that 2025 marked a significant step in the company’s evolution into a globally integrated healthcare platform. He noted that PureHealth’s expansion into international markets, combined with its focus on specialised care services, is laying the foundation for a more resilient and connected healthcare ecosystem.
Meanwhile, Founder and Managing Director Farhan Malik emphasised that the Group’s strong financial performance enables it to balance rewarding shareholders and reinvesting in future growth. He pointed out that PureHealth continues to invest both organically—through technology and capacity—and inorganically through strategic acquisitions that enhance its global footprint.
A key highlight of the Group’s strategy is its expanding international presence. With operations now spanning the UAE, the United States, the United Kingdom, Greece, and Cyprus, PureHealth has evolved into a diversified global healthcare organisation, with nearly half of its asset base located outside the UAE.
The company’s growth trajectory has also been supported by increasing patient volumes, enhanced clinical capabilities, and a strong focus on innovation, including the integration of AI-driven healthcare solutions. These advancements have contributed to improved operational efficiency and enhanced patient outcomes across its network.
The approved dividend will be distributed in two equal semi-annual instalments, reflecting a structured approach to shareholder returns while ensuring financial flexibility for future investments.
Industry analysts note that the move highlights PureHealth’s confidence in its financial stability and long-term growth strategy. By maintaining a balanced approach between returns and reinvestment, the company is well-positioned to navigate evolving market dynamics while continuing to expand its global presence.
The Group’s performance also reflects broader trends within the healthcare sector, where demand for high-quality services, advanced medical technologies, and integrated care solutions continues to rise. As governments and private players invest in healthcare infrastructure, companies with strong operational capabilities and scalable models are increasingly gaining a competitive edge.
PureHealth’s strategy of combining healthcare services (Care) and insurance solutions (Cover) has enabled it to build a comprehensive ecosystem that supports both patient care and financial sustainability. This integrated approach is expected to play a key role in driving future growth.
Looking ahead, the company is expected to continue focusing on innovation, international expansion, and operational excellence, reinforcing its ambition to become a leading global healthcare provider.
The approval of the AED 600 million dividend not only reflects strong financial performance but also signals confidence in PureHealth’s ability to sustain growth, deliver value, and shape the future of healthcare both regionally and globally.
